INMB vs REGN · rev $50.0K vs P/E 14, rev $4.29B
INmune Bio Inc (INMB) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
INMB currently screens at market cap $33.5M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the INMB and REGN stock pages for the full models.
Not investment advice.